董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Johnston | 男 | Independent Director | 66 | 16.93万美元 | 31.35 | 2025-08-11 |
| Rekha Hemrajani | 女 | Independent Director | 57 | 17.93万美元 | 26.93 | 2025-08-11 |
| Yasir Al Wakeel | 男 | Independent Director | 45 | 16.93万美元 | 26.93 | 2025-08-11 |
| Will Brooke | 男 | Independent Director | 70 | 18.68万美元 | 32.74 | 2025-08-11 |
| Maher Masoud | 男 | President, Chief Executive Officer and Director | 51 | 268.77万美元 | 81.46 | 2025-08-11 |
| Cynthia Lynne Collins | -- | Director | -- | 未披露 | 未持股 | 2025-08-11 |
| Patrick J Balthrop Sr | -- | Independent Director | -- | 16.93万美元 | 19.54 | 2025-08-11 |
| Stanley C. Erck | 男 | Independent Director | 78 | 17.68万美元 | 54.52 | 2025-08-11 |
| Richard H. Douglas | 男 | Non-Executive Chairman of the Board | 73 | 20.43万美元 | 37.02 | 2025-08-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Maher Masoud | 男 | President, Chief Executive Officer and Director | 51 | 268.77万美元 | 81.46 | 2025-08-11 |
| David I. Sandoval | -- | Senior Vice President, General Counsel and Corporate Secretary | -- | 未披露 | 未持股 | 2025-08-11 |
| Douglas Swirsky | 男 | Chief Financial Officer and Principal Accounting Officer | -- | 122.51万美元 | 25.99 | 2025-08-11 |
董事简历
中英对照 | 中文 | 英文- John Johnston
-
John Johnston，他曾一直担任Midatech公司的董事会的非执行成员（2014年11月13日以来）。2014年12月以来，他曾一直担任Constellation Healthcare Technologies公司（AIM：CHT）的非执行主席。他曾担任Nomura Code Securities公司（经纪公司）的负责机构销售的董事总经理（从2011年4月到2013年4月）。从2008年到2011年，他曾担任销售和交易董事，任职于Seymour Pierce投资银行。他于2003年创立Revera Asset Management公司，在那里他曾监管一个投资信托、一个单位信托、一个对冲基金，直到2007年。从2000年到2003年，他曾担任Legg Mason （NYSE：LM）公司的董事，负责小公司技术和风险资本信托。此前，他曾担任Murray Johnstone公司的小公司主管（从1998年到2000年）。从1992年到1997年，他曾担任Scottish Amicable公司的小公司主管，随后任职Ivory & Sime公司1年，并再次担任小公司主管（从1997年到1998年）。他的投资职业生涯始于1981年任职the Royal Bank of Scotland公司的受托人与投资部门，后于1985年任职General Accident公司，担任零售基金负责人，随后任职Scottish Amicable公司。他目前担任Flowgroup公司和Action Hotels公司的非执行董事。
John Johnston has served on Board since January 2016. Mr. Johnston previously served on the board of directors of Midatech Pharma from December 2014 to February 2019 Flow Group from August 2013 to October 2017 Action Hotels from December 2013 to December 2018 and Constellation Healthcare Technologies from December 2014 to January 2017. From August 2011 to April 2013 Mr. Johnston served as managing director of institutional sales at Nomura Code, and from 2008 to 2011 he was director of sales and trading at Seymour Pierce. In 2003 Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. Mr. Johnston began his investment career at the Royal Bank of Scotland and previously held positions at Legg Mason Investors and Murray Johnston. Mr. Johnston received his B.A. in commerce from Abertay University and his M.B.A. from the University of Dundee. - John Johnston，他曾一直担任Midatech公司的董事会的非执行成员（2014年11月13日以来）。2014年12月以来，他曾一直担任Constellation Healthcare Technologies公司（AIM：CHT）的非执行主席。他曾担任Nomura Code Securities公司（经纪公司）的负责机构销售的董事总经理（从2011年4月到2013年4月）。从2008年到2011年，他曾担任销售和交易董事，任职于Seymour Pierce投资银行。他于2003年创立Revera Asset Management公司，在那里他曾监管一个投资信托、一个单位信托、一个对冲基金，直到2007年。从2000年到2003年，他曾担任Legg Mason （NYSE：LM）公司的董事，负责小公司技术和风险资本信托。此前，他曾担任Murray Johnstone公司的小公司主管（从1998年到2000年）。从1992年到1997年，他曾担任Scottish Amicable公司的小公司主管，随后任职Ivory & Sime公司1年，并再次担任小公司主管（从1997年到1998年）。他的投资职业生涯始于1981年任职the Royal Bank of Scotland公司的受托人与投资部门，后于1985年任职General Accident公司，担任零售基金负责人，随后任职Scottish Amicable公司。他目前担任Flowgroup公司和Action Hotels公司的非执行董事。
- John Johnston has served on Board since January 2016. Mr. Johnston previously served on the board of directors of Midatech Pharma from December 2014 to February 2019 Flow Group from August 2013 to October 2017 Action Hotels from December 2013 to December 2018 and Constellation Healthcare Technologies from December 2014 to January 2017. From August 2011 to April 2013 Mr. Johnston served as managing director of institutional sales at Nomura Code, and from 2008 to 2011 he was director of sales and trading at Seymour Pierce. In 2003 Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. Mr. Johnston began his investment career at the Royal Bank of Scotland and previously held positions at Legg Mason Investors and Murray Johnston. Mr. Johnston received his B.A. in commerce from Abertay University and his M.B.A. from the University of Dundee.
- Rekha Hemrajani
-
Rekha Hemrajani自2020年8月成立以来一直担任我们的首席执行官，并担任我们的董事会成员。Hemrajani女士是一位经验丰富的战略领导者，帮助生物技术公司进行企业战略和企业融资，以及通过企业发展建立产品管道。她在公共和私人生物制药公司、Bulge Bracket投资银行拥有丰富的高级管理经验。Hemrajani女士最近担任Aravive，Inc.的总裁兼首席执行官纳斯达克:ARAV，2020年1月至2020年4月。Hemrajani女士曾于2019年担任Arcus Biosciences的首席财务官兼首席运营官，领导财务，投资者关系，企业沟通，业务和企业发展，战略规划和人力资源。在加入Arcus之前，Hemrajani女士于2016年至2019年担任Rapt Therapeutics（纳斯达克股票代码:RAPT）的首席运营官，2014年期间担任Sagimet Biosciences的首席财务官，担任生物制药公司和投资基金的顾问，担任Onyx Pharmaceuticals（NASDAQ:ONXX，2012-2013年被Amgen以104亿美元收购），2003-2011年担任Exelixis（NASDAQ:EXEL）业务开发副总裁。Hemrajani女士目前是ALX Oncology（纳斯达克市场代码:ALXO）和Adverum Biotechnologies（纳斯达克市场代码:ADVM）的董事。Hemrajani女士拥有西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）工商管理硕士学位和密歇根大学（University of Michigan）理学学士学位。
Rekha Hemrajani has served as a member of Lb Pharmaceuticals Inc's board of directors since September 2025. Ms. Hemrajani has served as a member of the board of directors of ALX Oncology Holdings Inc. since April 2020, MaxCyte, Inc. since June 2021, and BioAge Labs since August of 2021. Ms. Hemrajani served as Chief Executive Officer and Director of Jiya Acquisition Corporation from August 2020 to November 2022. She previously served as President, Chief Executive Officer & Director of Aravive, Inc., a clinical stage biotechnology company, from January 2020 to April 2020. From March 2019 to September 2019, Ms. Hemrajani served as the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company. From March 2016 to March 2019, she served as Chief Operating Officer of RAPT Therapeutics, Inc., a biotechnology company. From February 2015 to March 2016, Ms. Hemrajani served as Chief Financial Officer and Senior Vice President of Business and Financial Operations at Sagimet Biosciences, Inc., a biotechnology company. From November 2013 to January 2015, Ms. Hemrajani advised privately held companies on strategic corporate development and financing activities at Ravinia Consulting, a consulting firm she founded. She previously served as a director of Adverum Biotechnologies, Inc., Aravive, Inc. and Jiya Acquisition Corp. Ms. Hemrajani holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University. - Rekha Hemrajani自2020年8月成立以来一直担任我们的首席执行官，并担任我们的董事会成员。Hemrajani女士是一位经验丰富的战略领导者，帮助生物技术公司进行企业战略和企业融资，以及通过企业发展建立产品管道。她在公共和私人生物制药公司、Bulge Bracket投资银行拥有丰富的高级管理经验。Hemrajani女士最近担任Aravive，Inc.的总裁兼首席执行官纳斯达克:ARAV，2020年1月至2020年4月。Hemrajani女士曾于2019年担任Arcus Biosciences的首席财务官兼首席运营官，领导财务，投资者关系，企业沟通，业务和企业发展，战略规划和人力资源。在加入Arcus之前，Hemrajani女士于2016年至2019年担任Rapt Therapeutics（纳斯达克股票代码:RAPT）的首席运营官，2014年期间担任Sagimet Biosciences的首席财务官，担任生物制药公司和投资基金的顾问，担任Onyx Pharmaceuticals（NASDAQ:ONXX，2012-2013年被Amgen以104亿美元收购），2003-2011年担任Exelixis（NASDAQ:EXEL）业务开发副总裁。Hemrajani女士目前是ALX Oncology（纳斯达克市场代码:ALXO）和Adverum Biotechnologies（纳斯达克市场代码:ADVM）的董事。Hemrajani女士拥有西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）工商管理硕士学位和密歇根大学（University of Michigan）理学学士学位。
- Rekha Hemrajani has served as a member of Lb Pharmaceuticals Inc's board of directors since September 2025. Ms. Hemrajani has served as a member of the board of directors of ALX Oncology Holdings Inc. since April 2020, MaxCyte, Inc. since June 2021, and BioAge Labs since August of 2021. Ms. Hemrajani served as Chief Executive Officer and Director of Jiya Acquisition Corporation from August 2020 to November 2022. She previously served as President, Chief Executive Officer & Director of Aravive, Inc., a clinical stage biotechnology company, from January 2020 to April 2020. From March 2019 to September 2019, Ms. Hemrajani served as the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company. From March 2016 to March 2019, she served as Chief Operating Officer of RAPT Therapeutics, Inc., a biotechnology company. From February 2015 to March 2016, Ms. Hemrajani served as Chief Financial Officer and Senior Vice President of Business and Financial Operations at Sagimet Biosciences, Inc., a biotechnology company. From November 2013 to January 2015, Ms. Hemrajani advised privately held companies on strategic corporate development and financing activities at Ravinia Consulting, a consulting firm she founded. She previously served as a director of Adverum Biotechnologies, Inc., Aravive, Inc. and Jiya Acquisition Corp. Ms. Hemrajani holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
- Yasir Al Wakeel
-
Yasir Al Wakeel自2020年8月起担任公司发展首席财务官主管。在加入我们公司之前，Al-Wakeel博士于2017年7月至2020年5月担任NeonTherapeutics，Inc.首席财务官。此前，Al-Wakeel博士曾于2015年8月至2017年7月担任MerrimackPharmaceuticals，Inc.首席财务官兼企业发展主管。Al-Wakeel博士此前曾于2008年至2015年在瑞士信贷（Credit Suisse）（一家投资银行公司）担任各种职务。在瑞士信贷（Credit Suisse）任职期间，Al-Wakeel博士担任梦百合投资银行业务总监，专注于生物技术，在担任该职位之前，他是一名股票研究分析师，负责生物技术和特种制药部门。在加入Credit Suisse之前，Al-Wakeel博士是一名执业医师，同时担任临床和学术医疗职位。Al-Wakeel博士在牛津大学（Oxford University）获得医学与外科BCH博士学位，并在剑桥大学（Cambridge University）获得神学硕士学位。
Yasir Al Wakeel has served as a member of Vicore Pharma Holding Ab's Board since May 2024. Dr. Al Wakeel is a seasoned executive, board member, and strategic advisor to biotechnology companies. Dr. Al Wakeel currently serves as the Chief Executive Officer of Vesalius Therapeutics, a biotechnology company, and as CEO Partner at Flagship Pioneering, a life sciences innovation enterprise. Dr. Al Wakeel has operational experience running biotech companies, as well as earlier in his career, finance and business development functions, having worked at both public and private biotechnology companies. Prior to his roles in the biotechnology industry, Dr. Al Wakeel held senior roles in investment banking, serving as both an equity analyst and in corporate finance. Dr. Al Wakeel currently serves on the boards of directors of MaxCyte, Inc., a cell engineering company, and Vesalius Therapeutics. Dr. Al Wakeel earned his Bachelor of Medicine from Oxford University and his Masters in Theology at the University of Cambridge. - Yasir Al Wakeel自2020年8月起担任公司发展首席财务官主管。在加入我们公司之前，Al-Wakeel博士于2017年7月至2020年5月担任NeonTherapeutics，Inc.首席财务官。此前，Al-Wakeel博士曾于2015年8月至2017年7月担任MerrimackPharmaceuticals，Inc.首席财务官兼企业发展主管。Al-Wakeel博士此前曾于2008年至2015年在瑞士信贷（Credit Suisse）（一家投资银行公司）担任各种职务。在瑞士信贷（Credit Suisse）任职期间，Al-Wakeel博士担任梦百合投资银行业务总监，专注于生物技术，在担任该职位之前，他是一名股票研究分析师，负责生物技术和特种制药部门。在加入Credit Suisse之前，Al-Wakeel博士是一名执业医师，同时担任临床和学术医疗职位。Al-Wakeel博士在牛津大学（Oxford University）获得医学与外科BCH博士学位，并在剑桥大学（Cambridge University）获得神学硕士学位。
- Yasir Al Wakeel has served as a member of Vicore Pharma Holding Ab's Board since May 2024. Dr. Al Wakeel is a seasoned executive, board member, and strategic advisor to biotechnology companies. Dr. Al Wakeel currently serves as the Chief Executive Officer of Vesalius Therapeutics, a biotechnology company, and as CEO Partner at Flagship Pioneering, a life sciences innovation enterprise. Dr. Al Wakeel has operational experience running biotech companies, as well as earlier in his career, finance and business development functions, having worked at both public and private biotechnology companies. Prior to his roles in the biotechnology industry, Dr. Al Wakeel held senior roles in investment banking, serving as both an equity analyst and in corporate finance. Dr. Al Wakeel currently serves on the boards of directors of MaxCyte, Inc., a cell engineering company, and Vesalius Therapeutics. Dr. Al Wakeel earned his Bachelor of Medicine from Oxford University and his Masters in Theology at the University of Cambridge.
- Will Brooke
-
Will Brooke自2004年3月以来一直在我们的董事会任职。Brooke先生是Harbert Management Corporation（HMC）的有限合伙人，他于1993年联合创立了该公司，最近于2003年7月至2014年12月担任其风险资本基金家族的执行副总裁兼管理合伙人。30多年来，Brooke先生一直为早期和成长型公司提供咨询和投资，此前曾任职于NContact，Inc.，Novamin Technology，Inc.和Emageon Corporation等多家制药和医疗设备公司的董事会。自2018年12月以来，他还担任KPX，LLC的董事会成员，该公司是一家环境、社会和治理咨询公司，服务于投资和咨询行业。在加入HMC之前，Brooke先生从事了十年的法律工作。布鲁克先生在阿拉巴马大学获得商业管理学士学位和法学博士学位。
Will Brooke has served on Board since March 2004. Mr. Brooke is a limited partner of Harbert Management Corporation, or HMC, which he co-founded in 1993 most recently serving as EVP and Managing Partner of its venture capital funds family from July 2003 to December 2014. Mr. Brooke has been advising and investing in early-stage and growth companies for more than 30 years, and previously served on the boards of numerous pharmaceutical and medical equipment companies such as nContact, Inc., NovaMin Technology, Inc. and Emageon Corporation. Since December 2018 he has also served as a board member of KPX, LLC, an environmental, social and governance advisory firm serving the investment and advisory sectors. Prior to joining HMC, Mr. Brooke practiced law for a decade. Mr. Brooke received a B.S. in Business Management and a J.D. from the University of Alabama. - Will Brooke自2004年3月以来一直在我们的董事会任职。Brooke先生是Harbert Management Corporation（HMC）的有限合伙人，他于1993年联合创立了该公司，最近于2003年7月至2014年12月担任其风险资本基金家族的执行副总裁兼管理合伙人。30多年来，Brooke先生一直为早期和成长型公司提供咨询和投资，此前曾任职于NContact，Inc.，Novamin Technology，Inc.和Emageon Corporation等多家制药和医疗设备公司的董事会。自2018年12月以来，他还担任KPX，LLC的董事会成员，该公司是一家环境、社会和治理咨询公司，服务于投资和咨询行业。在加入HMC之前，Brooke先生从事了十年的法律工作。布鲁克先生在阿拉巴马大学获得商业管理学士学位和法学博士学位。
- Will Brooke has served on Board since March 2004. Mr. Brooke is a limited partner of Harbert Management Corporation, or HMC, which he co-founded in 1993 most recently serving as EVP and Managing Partner of its venture capital funds family from July 2003 to December 2014. Mr. Brooke has been advising and investing in early-stage and growth companies for more than 30 years, and previously served on the boards of numerous pharmaceutical and medical equipment companies such as nContact, Inc., NovaMin Technology, Inc. and Emageon Corporation. Since December 2018 he has also served as a board member of KPX, LLC, an environmental, social and governance advisory firm serving the investment and advisory sectors. Prior to joining HMC, Mr. Brooke practiced law for a decade. Mr. Brooke received a B.S. in Business Management and a J.D. from the University of Alabama.
- Maher Masoud
-
Maher Masoud自2020年1月起担任我们的执行副总裁and General Counsel，此前于2017年5月至2020年1月担任我们的法律副总裁。从2015年7月到2017年5月，Masoud先生担任Wellstat Management Company的助理总法律顾问兼公司秘书，此前曾担任Rossi/Masoud LLC的联合创始合伙人，这是一家专门从事生物技术、制药和IT行业的律师事务所。此前，从2006年到2012年，Masoud先生是Human GenomeSciences，Inc.的公司律师。Masoud先生在密歇根州立大学法学院获得法学博士学位，在马里兰大学获得细胞和分子生物学遗传学学士学位。马苏德先生是马里兰州律师协会的成员。
Maher Masoud has served as executive vice president and general counsel since January 2020 and previously as vice president of legal from May 2017 to January 2020. He was appointed as corporate secretary in July 2021. From July 2015 to May 2017 Mr. Masoud served as assistant general counsel and corporate secretary for Wellstat Management Company and previously served as co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors. Previously, Mr. Masoud was a corporate attorney at Human Genome Sciences, Inc. from 2006 until 2012. Mr. Masoud received his J.D. from Michigan State University College of Law and a B.S. in cell and molecular biology genetics from the University of Maryland. Mr. Masoud is a member of the Maryland state bar. - Maher Masoud自2020年1月起担任我们的执行副总裁and General Counsel，此前于2017年5月至2020年1月担任我们的法律副总裁。从2015年7月到2017年5月，Masoud先生担任Wellstat Management Company的助理总法律顾问兼公司秘书，此前曾担任Rossi/Masoud LLC的联合创始合伙人，这是一家专门从事生物技术、制药和IT行业的律师事务所。此前，从2006年到2012年，Masoud先生是Human GenomeSciences，Inc.的公司律师。Masoud先生在密歇根州立大学法学院获得法学博士学位，在马里兰大学获得细胞和分子生物学遗传学学士学位。马苏德先生是马里兰州律师协会的成员。
- Maher Masoud has served as executive vice president and general counsel since January 2020 and previously as vice president of legal from May 2017 to January 2020. He was appointed as corporate secretary in July 2021. From July 2015 to May 2017 Mr. Masoud served as assistant general counsel and corporate secretary for Wellstat Management Company and previously served as co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors. Previously, Mr. Masoud was a corporate attorney at Human Genome Sciences, Inc. from 2006 until 2012. Mr. Masoud received his J.D. from Michigan State University College of Law and a B.S. in cell and molecular biology genetics from the University of Maryland. Mr. Masoud is a member of the Maryland state bar.
- Cynthia Lynne Collins
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Patrick J Balthrop Sr
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Stanley C. Erck
-
Stanley C. Erck， 从2011年4月起，他担任Novavax, Inc.的首席执行官。从2010年2月至2011年4月，他担任Novavax, Inc.的执行主席和董事，从2009年6月起，担任董事。从2000年至2008年，他担任疫苗开发公司Iomai Corporation的总裁、首席执行官和董事，该公司于2008年被Intercell收购。在此之前，他曾担任上市免疫公司Procept、Integrated Genetics（现在是Genzyme Corporation）、Baxter International的领导层职位。他目前是BioCryst Pharmaceuticals、MaxCyte, Inc.、和MdBio Foundation的董事会成员。
Stanley C. Erck,Novavax, Inc.,President and Chief Executive Officer of Novavax, Inc. April 2011 to present.Interim Chief Financial Officer (November 2017 to March 2018).Executive Chairman (February 2010 to April 2011).Iomai Corporation President and Chief Executive Officer (2000 to 2008 when it was acquired by Intercell AG).Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International.M.B.A., University of Chicago.Bachelor of Science in Economics, University of Illinois. - Stanley C. Erck， 从2011年4月起，他担任Novavax, Inc.的首席执行官。从2010年2月至2011年4月，他担任Novavax, Inc.的执行主席和董事，从2009年6月起，担任董事。从2000年至2008年，他担任疫苗开发公司Iomai Corporation的总裁、首席执行官和董事，该公司于2008年被Intercell收购。在此之前，他曾担任上市免疫公司Procept、Integrated Genetics（现在是Genzyme Corporation）、Baxter International的领导层职位。他目前是BioCryst Pharmaceuticals、MaxCyte, Inc.、和MdBio Foundation的董事会成员。
- Stanley C. Erck,Novavax, Inc.,President and Chief Executive Officer of Novavax, Inc. April 2011 to present.Interim Chief Financial Officer (November 2017 to March 2018).Executive Chairman (February 2010 to April 2011).Iomai Corporation President and Chief Executive Officer (2000 to 2008 when it was acquired by Intercell AG).Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International.M.B.A., University of Chicago.Bachelor of Science in Economics, University of Illinois.
- Richard H. Douglas
-
Richard H. Douglas，曾在Aldeyra Therapeutics， Inc.任职。自2016年9月起担任董事会成员。Douglas博士曾担任Genzyme Corporation的高级副总裁，负责企业发展。从1989年到2011年，他领导Genzyme Corporation的企业发展团队，并参与了许多收购、许可、融资、合资企业和战略联盟。从1982年到1989年与Genzyme公司（现为Sanofi Genzyme）合并，Douglas博士担任Integrated Genetics公司的科学和企业发展能力。目前，他是Novavax， Inc.（上市的临床阶段疫苗公司）的董事会成员；MaxCyte, Inc.，一家公开交易的仪器和免疫治疗公司；以及密歇根大学技术转移国家顾问委员会。他持有Michigan大学的化学学士学位和California大学， Berkeley的生物化学博士学位，他是the California Institute of Technology的Leroy Hood实验室的博士后研究员。
Richard H. Douglas,was formerly Senior Vice President, Corporate Development of Genzyme Corporation. From 1989 to 2011, he led the Corporate Development team at Genzyme, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until the merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly-traded commercial vaccine company; chairs the Board of Directors of MaxCyte, Inc., a publicly traded instrument company; and is on the University of Michigan Innovation Partnerships National Advisory Board. Dr. Douglas is also an advisor to Red Sky Partners LLC. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in the laboratory of Leroy Hood at the California Institute of Technology. - Richard H. Douglas，曾在Aldeyra Therapeutics， Inc.任职。自2016年9月起担任董事会成员。Douglas博士曾担任Genzyme Corporation的高级副总裁，负责企业发展。从1989年到2011年，他领导Genzyme Corporation的企业发展团队，并参与了许多收购、许可、融资、合资企业和战略联盟。从1982年到1989年与Genzyme公司（现为Sanofi Genzyme）合并，Douglas博士担任Integrated Genetics公司的科学和企业发展能力。目前，他是Novavax， Inc.（上市的临床阶段疫苗公司）的董事会成员；MaxCyte, Inc.，一家公开交易的仪器和免疫治疗公司；以及密歇根大学技术转移国家顾问委员会。他持有Michigan大学的化学学士学位和California大学， Berkeley的生物化学博士学位，他是the California Institute of Technology的Leroy Hood实验室的博士后研究员。
- Richard H. Douglas,was formerly Senior Vice President, Corporate Development of Genzyme Corporation. From 1989 to 2011, he led the Corporate Development team at Genzyme, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until the merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly-traded commercial vaccine company; chairs the Board of Directors of MaxCyte, Inc., a publicly traded instrument company; and is on the University of Michigan Innovation Partnerships National Advisory Board. Dr. Douglas is also an advisor to Red Sky Partners LLC. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in the laboratory of Leroy Hood at the California Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Maher Masoud
Maher Masoud自2020年1月起担任我们的执行副总裁and General Counsel，此前于2017年5月至2020年1月担任我们的法律副总裁。从2015年7月到2017年5月，Masoud先生担任Wellstat Management Company的助理总法律顾问兼公司秘书，此前曾担任Rossi/Masoud LLC的联合创始合伙人，这是一家专门从事生物技术、制药和IT行业的律师事务所。此前，从2006年到2012年，Masoud先生是Human GenomeSciences，Inc.的公司律师。Masoud先生在密歇根州立大学法学院获得法学博士学位，在马里兰大学获得细胞和分子生物学遗传学学士学位。马苏德先生是马里兰州律师协会的成员。
Maher Masoud has served as executive vice president and general counsel since January 2020 and previously as vice president of legal from May 2017 to January 2020. He was appointed as corporate secretary in July 2021. From July 2015 to May 2017 Mr. Masoud served as assistant general counsel and corporate secretary for Wellstat Management Company and previously served as co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors. Previously, Mr. Masoud was a corporate attorney at Human Genome Sciences, Inc. from 2006 until 2012. Mr. Masoud received his J.D. from Michigan State University College of Law and a B.S. in cell and molecular biology genetics from the University of Maryland. Mr. Masoud is a member of the Maryland state bar.- Maher Masoud自2020年1月起担任我们的执行副总裁and General Counsel，此前于2017年5月至2020年1月担任我们的法律副总裁。从2015年7月到2017年5月，Masoud先生担任Wellstat Management Company的助理总法律顾问兼公司秘书，此前曾担任Rossi/Masoud LLC的联合创始合伙人，这是一家专门从事生物技术、制药和IT行业的律师事务所。此前，从2006年到2012年，Masoud先生是Human GenomeSciences，Inc.的公司律师。Masoud先生在密歇根州立大学法学院获得法学博士学位，在马里兰大学获得细胞和分子生物学遗传学学士学位。马苏德先生是马里兰州律师协会的成员。
- Maher Masoud has served as executive vice president and general counsel since January 2020 and previously as vice president of legal from May 2017 to January 2020. He was appointed as corporate secretary in July 2021. From July 2015 to May 2017 Mr. Masoud served as assistant general counsel and corporate secretary for Wellstat Management Company and previously served as co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors. Previously, Mr. Masoud was a corporate attorney at Human Genome Sciences, Inc. from 2006 until 2012. Mr. Masoud received his J.D. from Michigan State University College of Law and a B.S. in cell and molecular biology genetics from the University of Maryland. Mr. Masoud is a member of the Maryland state bar.
- David I. Sandoval
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Douglas Swirsky
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介